Fresh from the pipeline: Tigecycline

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 809-810

  Wenzel, Richard ^a   Bate, Guy ^b   Kirkpatrick, Peter ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

^c Nature Reviews Drug Discovery   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CILASTATIN PLUS IMIPENEM; DAPTOMYCIN; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; METICILLIN; MINOCYCLINE; NEW DRUG; RIBOSOME PROTEIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE;

ABDOMINAL INFECTION; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; PRIORITY JOURNAL; SKIN INFECTION; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ECONOMICS; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEGAL ASPECT; META ANALYSIS; METHODOLOGY; MICROBIOLOGY; PHARMACEUTICS;

ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; HUMANS; INFECTION; INJECTIONS, INTRAVENOUS; META-ANALYSIS; MINOCYCLINE; MOLECULAR STRUCTURE; TECHNOLOGY, PHARMACEUTICAL;

EID: 27644546800     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1857     Document Type: Article

References (13)

1. Walsh, C. Where will new antibiotics come from? Nature. Rev. Microbiol. 1, 65-69 (2003).
2. Chopra, I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1, 464-469 (2001).
3. Sum, P. E. & Petersen, P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9, 1459-1462 (1999).
4. Petersen, P. J. et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43, 738-744 (1999).
5. FDA labelling information [online], (2005).
6. Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
7. Wenzel, R. P. & Edmond, M. B. The impact of hospital-acquired bloodstream infections. Emerging Infect. Dis. 7, 174-177 (2001).
8. Ibrahim, E. H. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118, 146-155 (2000).
9. Doern, G. V. et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: Have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41, 139-148 (2005).
10. Noskin, G. A. Tigecycline: A new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41, s303-s314 (2005).
11. Ellis-Grosse, E. J. et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin. Infect. Dis. 41, s341-353 (2005).
12. Babinchak, T. et al. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin. Infect. Dis. 41, s354-s367 (2005).
13. IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).